SCHEMBL3653383

SCHEMBL3653383

Fc1ccc(-c2nc3c(-c4ccc5ccccc5c4)ccnc3n2C2CCNCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.41
HTR6 P50406 1/20 0.40
BRD4 O60885 3/20 0.40
BRDT Q58F21 3/20 0.40
MAPK13 O15264 2/20 0.39
MAPK12 P53778 2/20 0.39
MAPK11 Q15759 2/20 0.39
RIPK2 O43353 1/20 0.39
DYRK3 O43781 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PRKCG P05129 1/20 0.39
LCK P06239 1/20 0.39
LYN P07948 1/20 0.39
RET P07949 1/20 0.39
PIM1 P11309 1/20 0.39
PRKACA P17612 1/20 0.39
MAPK1 P28482 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3646892 0.93 NR1H4 (0.40) MAPK14BRD4MAPK11PIM1MAPK9
SCHEMBL3646647 0.93 NR1H4 (0.41) MAPK14BRD4MAPK11PIM1MAPK9
SCHEMBL3652343 0.91 MAPK14 (0.40) MAPK14HTR6NR1H4
SCHEMBL3653517 0.91 NR1H4 (0.39) MAPK14BRD4BRDTPIM1MAPK9
SCHEMBL3647836 0.91 MAPK11 (0.41) MAPK14MAPK13MAPK12MAPK11PIM1
SCHEMBL3648962 0.91 MAPK14 (0.38) MAPK14HTR6BRD4BRDTMAPK13
SCHEMBL3650998 0.90 NR1H4 (0.38) MAPK14BRD4MAPK11PIM1MAPK9
SCHEMBL3652977 0.90 NR1H4 (0.38) MAPK14HTR6BRD4MAPK11PIM1
SCHEMBL3648574 0.90 NR1H4 (0.38) MAPK14PIM1NR1H4
SCHEMBL3650080 0.89 BRD4 (0.40) MAPK14HTR6BRD4MAPK11MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185556-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM Wyeth a Corporation of the State of Delaware (US) 2010-05-19 EP claimed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US claimed
WO-2009029609-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-05 WO claimed
EP-2185556-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM Wyeth a Corporation of the State of Delaware (US) 2010-05-19 EP disclosed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US disclosed
WO-2009029609-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WNT1, CTNNB1, WNT3A MAPK14 888/4885HTR6 110/4885BRD4 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.